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Currently, the surgical management of pancreas cancer is recognized around the world as inadequate. Despite a potentially
curative R0 resection, long-term survival is rare. There is a strong rationale for the use of chemotherapy in the operating room
to reduce local-regional of recurrent/progressive disease. Gemcitabine monotherapy administered by an intraperitoneal route in
the operating room with hyperthermia and then for long-term treatment postoperatively has a pharmacologic basis in that the
exposure of peritoneal surfaces to intraperitoneal gemcitabine is approximately 200–500 times the exposure that occurs within the
plasma. A standardized treatment with intraoperative and long-term chemotherapy that is well tolerated would greatly facilitate
further improvements in pancreas cancer treatment and may lead the way to an evolution of more successful treatment strategies




deaths in the United States of America with an estimate
of 37,660 deaths in 2011 [1]. Surgery represents the only
deﬁnitive treatment option, and complete tumor resection
is associated with better disease-free and overall patient
survival. Advances in surgical technique, anesthesia, and
perioperative care in the last two decades have led to a sub-
stantial decrease in perioperative mortality and morbidity
especially in large-volume centers. Unfortunately, only 10–
20% of patients diagnosed with pancreatic cancer are able to
undergo potentially curative surgery [2]. Furthermore, long-
term 5- or 10-year survival is rare, even after potentially
curative R0 resection. Recently, Cleary reported 18 of 123
(15%) 5-year survival; 4 of these 18 patients died of disease
after 5 years [3]. After curative resection, disease recurrence
has been documented in the local and regional area (50%),
on peritoneal surfaces (40–60%) and within the liver as
hepatic metastases (50–60%) [4].
1.1. Rationale for Intraperitoneal Gemcitabine. The mecha-
nisms of failure after pancreaticoduodenectomy are unclear.
One possible explanation for the large number of local and
regional failures is tumor dissemination and implantation
within the resection site during surgery. Conceptually, this
forms the basis for administration of perioperative and long-
term intraperitoneal chemotherapy. The major advantage of
intraperitoneal chemotherapy is the high drug level that can
beachievedlocallywithlowsystemicexposure[5].Asystem-
atic review of randomized control trials has established the
role of adjuvant perioperative intraperitoneal chemotherapy
in high-risk gastric cancer patients after potentially curative
resection [6]. Also, long-term intraperitoneal chemotherapy
has established eﬃcacy in ovarian cancer [7–9]. Success
of systemic chemotherapy in controlling local disease has
a weaker rationale and has never been conﬁrmed in ran-
domized trials. The pharmacokinetics of gemcitabine makes
it an excellent drug for intraperitoneal use. With evidence
mounting for use of intraperitoneal chemotherapy after
resection in ovarian and gastric cancer,a rationale for the use2 International Journal of Surgical Oncology
of intraperitoneal chemotherapy after curative resection in
pancreatic cancer should be explored with a formal protocol.
2. Washington Cancer InstitutePhase II Study




GU-2009-455) we have initiated a local-regional treatment
using gemcitabine monotherapy. After enrollment and
informed consent, a standard pancreatic resection is per-
formed, and, if necessary, there is pathologic conﬁrmation
of primary pancreatic adenocarcinoma. Patients with cancer
of the head of the pancreas and tail of the pancreas who have
a complete visible resection of disease are eligible.
Following cancer resection gemcitabine at 1000mg/m2 is
instilled into the peritoneal cavity in a chemotherapy solu-
tion containing 1.5% dextrose peritoneal dialysis solution.
The volume of peritoneal dialysis solution is 1.5L/m2.T h e r e
is a single inﬂow catheter that is placed in the anatomic
site from which the pancreatic cancer was removed. Four
outﬂow drains are positioned in the right upper quadrant,
left upper quadrant, and two within the pelvis. A heater
circulator(Belmont,Billerica,Mass)wasutilizedtomaintain
the chemotherapy solution at 43◦Ca tt h ei n ﬂ o wa n d4 1 ◦C
within the whole abdomen. The treatment lasts for 1 hour
and there is an open technique used with a vapor barrier
that allows continuous manipulation of the abdominal and
pelvic contents by the surgeon and uniform distribution of
the heated chemotherapy solution (Figure 1).
Prior to closing the abdominal incision an intraperi-
toneal port (Port-A-Cath, Smiths Medical MD, Inc., St. Paul,
Minn) is positioned. The port is accessed with a noncoring
right angle needle (Port-A-Cath Gripper Plus, Deltec, Inc.,
St. Paul, Minn) to temporarily maintain proper position for
u s ei n4t o6w e e k s[ 10]. When the patient has fully recovered
from surgery and the sutures have been removed from the
skin incision, the adjuvant intraperitoneal gemcitabine is
begun.Therearesixcycles,eachofwhichis4weeksinlength.
Gemcitabine at 1,000mg/m2 is given by intraperitoneal
administration on days 1, 8, and 15 of the 4-week cycle.
Results to date show that the hyperthermic intraperi-
toneal gemcitabine and the long-term intraperitoneal gem-
citabine are well tolerated. No grade III or IV toxicities were
observed. To date, seven patients have been treated with
hyperthermic gemcitabine as part of the pancreaticoduode-
nal resection, and the accrual process is ongoing.
As part of this phase I/II single institution study, a phar-
macokinetic analysis of hyperthermic intraperitoneal gem-
citabine is being performed. There is a standard dose of
1,000mg/m2 of gemcitabine in a standard volume of 1.5%
dextrose peritoneal dialysis solution (1.5L/m2). Peritoneal
ﬂuid, plasma, and urine samples are obtained at 15-
minute intervals throughout the 60 minutes of hyperthermic
intraperitoneal chemotherapy. The results as seen in a single
patient are presented in Figure 2. Similar data has been
obtained in 4 additional patients. The area under the curve
Figure 1: Hyperthermic intraperitoneal chemotherapy for treat-
ment of abdominal and pelvic surfaces following pancreaticoduo-
denectomy. To administer hyperthermic intraperitoneal chemo-
therapy there is one inﬂow catheter and four drainage catheters.
The chemotherapy solution is maintained at approximately 43◦C
at the inﬂow catheter and 41◦C throughout the whole abdomen.
Four smoke evacuators are placed around the periphery of the
open abdomen in order to create a “vapor barrier” above the
chemotherapy solution. The surgeon’s double-gloved hand is used
to maintain a uniform distribution of the heat and chemotherapy
solution.
ratio of concentration times time of intraperitoneal to
intravenous gemcitabine was 210. To date, no data regarding
gemcitabine within pancreatic tissues is available.
Six months of normothermic intraperitoneal gemc-
itabine using an intraperitoneal port was selected as an anal-
ogy to the current recommendation for use of intravenous
gemcitabine. Not only the schedule but also the doses of
intraperitoneal chemotherapy are the same as currently
recommended for systemic treatment. The route of admin-
istration in the current study is intraperitoneal rather than
intravenous.
3. Discussion:Summary of Randomized
Control Trials of Adjuvant Therapy for
PancreaticCancer
Realizing that the chances are small of surgical resection
alone being curative, there have been many studies analyzing
the beneﬁts of adjuvant therapy in pancreatic cancer. In 1985
the Gastrointestinal Study Group (GITSG) conducted a 2-
arm study trial randomizing patients into 5-ﬂuorouracil-
(5-FU-) based chemoradiation versus observation [11]. The
mean survival in the chemoradiation arm was 20 months
compared to 11 months in the observation arm. The 5-year
survival was 18% and 8%, respectively. The trial was able to
recruitonly43patientsin11yearsandhadtobeprematurely
closed due to slow accrual and signiﬁcant beneﬁt favoring
adjuvant chemoradiation.
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Figure 2: Pharmacology of intraoperative intraperitoneal gemc-
itabine in a patient with resected pancreas cancer. The drug was
used at 1,000mg/m2 in 3 liters of 1.5% dextrose peritoneal dialysis
solution administered intraperitoneally. The area under the curve
ratio of concentration × time intraperitoneal to intravenous was
210. Sixty-eight percent of the drug was cleared from the peritoneal
cavity in 60 minutes. Data were taken from the study of a single
patient but are similar to those in four other patients. The patient
has completed the long-term intraperitoneal gemcitabine without
incident.
designed to validate the result of the smaller GITSG trial
[12]. Adjuvant therapy was similar except that the GITSG
study used maintenance chemotherapy while the EORTC
trialdidnot.IntheEORTCtrial,218patientswithpancreatic
and ampullary cancer were recruited. Randomization was
to the observation group or radiotherapy with split-course
radiotherapy (40Gy) and concurrent 5-FU as a continuous
infusion. After a median followup of 11.7 years, there was
no diﬀerence in overall survival between the 2 arms. The
limitationsofthisstudywerethelackofmaintenancechemo-
therapy and a questionable statistical design that limited its
ability to detect a small beneﬁt for adjuvant chemoradiation.
The European Study Group for Pancreatic Cancer
(ESPAC) conducted a trial between 1994 and 2000 (ESPAC-
1) [13]. In the 2 × 2 factorial design, 145 patients were
randomized to the chemoradiotherapy arm, and 144 were
randomly assigned to no chemoradiotherapy. Radiation was
administered as a split course (total 50Gy), concurrent with
5-FU. There was no diﬀerence in the median survival (15.5
months in the chemoradiotherapy arm and 16.1 months
in the no-chemoradiation arm). In the ﬁnal results of the
ESPAC-1 trial, the median survival was 15.9 months in the
chemoradiotherapy arm and 17.9 months in the group not
assigned to receive chemoradiotherapy (P = 0.05) [14]. The
estimated5-yearsurvivalwas10%inthechemoradiotherapy
arm compared with 20% in those who did not receive chem-
oradiotherapy (P = 0.05).
With both EORTC and the ESPAC-1 studies showing no
survival beneﬁt, the evidence to support continued use of
adjuvant chemoradiotherapy in pancreatic cancer has been
markedly reduced. This leads to increased interest in clinical
trials using chemotherapy alone.
TheESPAC-1trialalsostudiedthebeneﬁtofabolusof5-
FU administered intravenously. A total of 289 patients were
randomized using the 2 ×2 factorial design and followed for
47 months [14]. The survival with chemotherapy was 20.1
months and without chemotherapy was 15.5. The survival
beneﬁt was evident not only with R0 but also with R1
resection.
In contrast to contradictory data for chemoradiation
therapy, clinical research with gemcitabine has shown it to be
a major advance in the treatment of pancreatic cancer. Gem-
citabine is a diﬂuorinated analog of the naturally occurring
nucleoside deoxycytidine and has shown signiﬁcant clinical
activity in a variety of solid tumors including pancreatic
cancer. A most recent and signiﬁcant study regarding the
use of adjuvant gemcitabine is the CONKO-001 (Charit´ e
Onkologie) study [15]. This multicenter randomized control
trial conducted between July 1998 and December 2004 was
designed to test the hypothesis that adjuvant chemotherapy
with gemcitabine administered after complete resection of
pancreaticcancerimproves disease-free survivalby6months
or more. A total of 368 patients with gross complete (R0 or
R1) resection of pancreatic cancer and no prior radiation or
chemotherapy were enrolled into 2 groups. One group of
patients was randomized to receive adjuvant chemotherapy
with 6 cycles of gemcitabine on days 1, 8, and 15 every
4w e e k s( n = 179), and the second group was observed
(n = 175). Median disease-free survival was 13.4 months
in the gemcitabine group and 6.9 months in the control
g r o u p .E s t i m a t e dd i s e a s e - f r e es u r v i v a la t3a n d5y e a r sw a s
23.5% and 16.5% in the gemcitabine group, and 7.5%
and 5.5% in the control group, respectively. These authors
concluded that treatment with gemcitabine for 6 months
after complete resection of pancreas cancer statistically
signiﬁcantly increases median and disease-free survival. A
recent abstract reporting followup in 2008 conﬁrms these
beneﬁts [16].
The eﬀect of gemcitabine on disease-free survival was
signiﬁcant in patients with either R0 or R1 resection. In the
follow-up analysis gemcitabine did improve the overall sur-
vival (gemcitabine 22.8 months versus control 20.2 months).
The most impressive statistic was the delayed development
of recurrent disease after complete resection of pancreatic
cancer compared with observation alone. This clinical trial
strongly supports use of gemcitabine as adjuvant chemother-
apy in resectable carcinoma of the pancreas.
Given the conﬂicting data concerning the use of chem-
oradiotherapy in resected pancreatic cancer, the optimal
treatment of patients in this setting remains controversial. In
Europe, chemotherapy with gemcitabine alone is generally
accepted as standard of care, whereas in the United States,
chemoradiation therapy is still commonly recommended.4 International Journal of Surgical Oncology
Recently, a multiagent chemotherapy regimen used to
treat patients with unresectable disease has shown increased
survival when compared to single-agent Gemzar. In 342
randomized patients the FOLFIRINOX regimen resulted in
a median overall survival of 11.1 months as compared to 6.8
months in the gemcitabine group. Clearly, this multiagent
chemotherapy regimen becomes a candidate for adjuvant
treatment of resected pancreas cancer [17].
4. IntraperitonealGemcitabine
Pharmacokinetics
Gemcitabine is a prodrug which has little or no cytotoxic
eﬀect. The drug is metabolized within tissue to the active
agent, gemcitabine triphosphate. The eﬃcacy of gemcitabine
has been correlated with concentrations of gemcitabine
triphosphate accumulated in peripheral blood mononuclear
cell (PBMC), which in turn is related to plasma concentra-
tion. The rate of intracellular accumulation of gemcitabine
triphosphate was highest when plasma gemcitabine was
about 20micromol/L [18]. Beyond this there is enzymatic
saturation, and further increase in plasma concentration
does not produce any increase in intracellular gemcitabine
triphosphate concentration.
There are two types of infusion regimens followed for
gemcitabine. First is the ﬁxed dose rate regimen: In this
regimen generally 1,000 or 1,500mg/m2 is infused during
100 or 150 minutes. The dose rate of 10mg/m2/min achieves
the target plasma concentration of 20micromol/L.
In contrast the standard dose therapy of gemcitabine
administered by intravenous infusion is 1000mg/m2 over
30 minutes once weekly for up to 7 weeks (or until toxicity
necessitates reducing or holding a dose), followed by a week
of rest from treatment. Subsequent cycles should consist of
infusions once weekly for 3 consecutive weeks out of every 4
weeks.
Much of the controversy about the use of gemcitabine in
further clinical trials has concerned the possible superiority
of ﬁxed dose rate over the standard dose schedule. It is a
known fact that the ﬁxed dose rate infusion achieves better
concentrations of gemcitabine triphosphate in PBMCs, but
the clinical beneﬁt of this is uncertain [18].
A criticism of the use of intraperitoneal gemcitabine in
carcinomaoftheovarywasthatbetterplasmaconcentrations
could be achieved by ﬁxed dose rate infusion of gemcitabine
than by intraperitoneal administration. In the study by
Sabbatini et al. plasma concentrations of intraperitoneal
gemcitabine administered were between 0.92–8.2micromol
which was considerably below the threshold for maximum
eﬀect (20micromol) [19]. However, this criticism ignores
the high likelihood that intraperitoneal chemotherapy acts
by direct uptake of the drug into cancer cells or peritoneal
implants. Furthermore, as Gandhi have pointed out, almost
all pharmacokinetic studies on gemcitabine have a caveat
that the cellular pharmacokinetic data are obtained from a
surrogate tissue (circulating peripheral blood mononuclear
cells) rather than from the target solid tumor tissue [18].
The gemcitabine drug levels within solid tumor tissue
are not known. Also, levels of gemcitabine-activating and
-inactivating enzymes within cancerous tissue such as
cytidine deaminase, deoxycytidine kinase, and nucleotidases
are not well deﬁned. It is merely an assumption that ﬁxed
dose rate infusion in comparison to intraperitoneal admin-
istration would result in greater area under the curves
(AUC) and/or peak levels of gemcitabine triphosphate in
tumor cells located at the peritoneal surface of the abdomen
and pelvis. Gandhi has suggested pharmacologic studies in
which tumor tissue is directly available for measurement of
gemcitabine triphosphate concentration.
Clinical and laboratory studies do show a theoretical
advantage of intraperitoneal versus intravenous gemcitabine
[20]. Pestieau and colleagues studied the pharmacokinetics
ofintraperitonealgemcitabineinaratmodel.Theareaunder
the curve ratio of intraperitoneal to systemic drug exposure
in the rat model was between 12.5 and 26.8 depending on
the dose of intraperitoneal gemcitabine. All tissue samples
showed an increased drug concentration when administered
with intraperitoneal hyperthermia as compared to a normo-
thermic state.
Sugarbaker and colleagues reviewed the data on intra-
peritoneal gemcitabine in humans by taking plasma and
peritoneal ﬂuid samples from patients in the operating
room [21]. These data showed that gemcitabine used with
heated intraoperative intraperitoneal administration at
1,000mg/m2 in 3 Liters had marked local-regional drug
exposure. The area under the curve ratio of concentration
times time for intraperitoneal to intravenous drug was 500.
In this study of a patient who had resected pancreas cancer
treated with intraperitoneal hyperthermic gemcitabine, con-
siderable beneﬁt was suggested by the pharmacologic data.
The adequate plasma concentration of 5.26mcg/mL
has been recommended [19]. In our patient presented in
Figure 2, the peak plasma concentration was 4.03mcg/mL,
veryclosetothetargetachievedbyaﬁxed-dose-rateinfusion.
Of course, the translation of the pharmacologic advantage
into an improvement in local-regional disease control re-
quires further clinical studies.
In a study involving nine patients with advanced pancre-
atic malignancy reported by Gamblin et al., intraperitoneal
chemotherapy was administered using indwelling peritoneal
catheters [22]. Intraperitoneal gemcitabine was well toler-
ated, and no signiﬁcant toxicities were noted. There was
rapid decrease in peritoneal gemcitabine concentration due
to almost total absorption of the intraperitoneally admin-
istered gemcitabine. Steady plasma concentrations were
reached early implying absorption of virtually all intraperi-
toneallyadministeredgemcitabine.Theseﬁndingscombined
with the fact that gemcitabine has low local toxicity argue
well for its use in intraperitoneal chemotherapy.
5. Intraperitoneal Gemcitabinein
OvarianCarcinoma
A phase 2 study using intraperitoneal cisplatin and gem-
citabine in carcinoma of the ovary was conducted by
Sabbatini et al. [19]. The patients selected were those withInternational Journal of Surgical Oncology 5
persistent disease documented by a second-look assessment.
The patients were given intraperitoneal cisplatin (75mg/m2)
on day 1 and intraperitoneal gemcitabine at 500mg/m2 on
days 1, 8, and 15 on a 28-day schedule for four courses.
The median time to treatment failure and overall survival
of 15.9 and 43.5 months, respectively, were consistent with
historical data in second-look-positive patients receiving
a variety of intraperitoneal platinum-based regimens for
consolidation. There was no apparent beneﬁt with intraperi-
toneal gemcitabine, and the authors attributed this to
the dense peritoneal ﬁbrosis that they encountered during
second-look surgery. The authors of this study (as discussed
earlier) have stated that the concentrations of intraperitoneal
gemcitabine in peripheral blood mononuclear cells were
determined to be much below the maximum therapeutic
values in plasma. Data regarding an increased local-regional
drug concentration and improved local-regional control of
cancer as a result of intraperitoneal administration was not
provided.
In the study by Sabbatini et al., patients were treated
using intraperitoneal cisplatin at 75mg/m2 on day 1 with
a dose escalation of gemcitabine at 500, 750, 1000, or
1250mg/m2 intraperitoneally on days 1, 8, and 15 of a 28-
day schedule for four courses [19]. The phase I dose-limiting
toxicity was grade 3 thrombocytopenia at day 15 on dose
level 1. The chemotherapy protocol was modiﬁed to cisplatin
(75mg/m2) on day 1 and gemcitabine at 500mg/m2 on days
1 and 8 of a 21-day schedule for four courses.
Of the 30 patients that were enrolled for the study, 9
were removed from the study; one each for hypersensitivity,
cellulitis, and intraperitoneal port malfunction, two for
progression of disease, and four for renal toxicity. Other
toxicities included grade 3 nausea (7%) and transient grade
3 neuropathy (3%). Grade 1 or 2 neuropathy was frequently
seen (80%). Five patients (17%) returned to the operating
room at a median of 6 months (range, 1–20 months) after
intraperitoneal therapy for evaluation of abdominal pain;
two patients had recurrence, and all had areas of ﬁbrous
tissue with encasement of the bowel. The peritoneal sclerosis
was, most likely, related to repeated doses of intraperitoneal
cisplatin. The lack of beneﬁt from intraperitoneal gemc-
itabine in ovarian cancer patients may be from poor drug
distribution and extensive peritoneal ﬁbrosis in this group
of patients.
6. ClinicalTrialsof GemcitabineAlone or in
Combination withOther Drugs in Patients
with UnresectablePancreasCancer
The current available evidence for treatment for pancreatic
cancer suggests that gemcitabine monotherapy chemother-
apy should be considered a valid treatment option. In
the important study reported by Burris and colleagues,
126 chemotherapy-na¨ ıve patients with unresectable pancre-
atic cancer were randomized to receive either intravenous
gemcitabine or 5-ﬂuorouracil. The primary endpoint was
a composite of pain measurements, weight, and perfor-
mance status [23]. Patients treated with gemcitabine derived
signiﬁcantly more clinical beneﬁt than those receiving 5-
ﬂuorouracil (23.8% versus 4.8%, respectively; P = 0.0022).
In addition there was a statistically signiﬁcant improvement
in overall survival (median: 5.65 versus 4.41 months, resp.)
with a 1-year survival rate of 18% in the gemcitabine cohort
compared with 2% in patients receiving 5-ﬂuorouracil (P<
0.002).
Berlin and colleagues published an ECOG phase 3 trial
including 327 patients with advanced carcinoma of the
pancreas [24]. They showed that 5-ﬂuorouracil, adminis-
tered in conjunction with gemcitabine, did not improve the
median survival of patients with advanced pancreatic carci-
noma compared with single-agent gemcitabine. The authors
concluded that further studies with other combinations
of gemcitabine and 5-ﬂuorouracil are not compelling and
clinical trial resources should address other combinations
and novel agents. Several other chemotherapy agents have
been tried in combination with gemcitabine.
Irinotecan with gemcitabine has not shown any beneﬁt
as compared to gemcitabine alone [25].
Thecombinationofgemcitabinewithcisplatinandoxali-
platin has been more encouraging. In a German multicenter
study, Heinemann et al. enrolled 195 patients to receive
either gemcitabine alone or in combination with cisplatin
[26]. These results supported the eﬃcacy and safety of
an every-2-week treatment with gemcitabine plus cisplatin.
Median overall survival and progression-free survival were
more favorable in the combination arm as compared with
gemcitabine alone, although the diﬀerence did not attain
statistical signiﬁcance. The French Multidisciplinary Clinical
Research Group (GERCOR)/Italian Group for the Study of
Gastrointestinal Tract Cancer (GISCAD) intergroup study
compared gemcitabine plus oxaliplatin to gemcitabine alone
[27]. The pooled analysis of the GERCOR/GISCAD inter-
groupstudyandtheGermanmulticenterstudyindicatesthat
the combination of gemcitabine with a platinum analog such
as oxaliplatin or cisplatin signiﬁcantly improves progression-
free survival and overall survival as compared to single-
agent gemcitabine in advanced pancreatic cancer especially
in patients with good performance status [28].
Scheithauer et al. reported on gemcitabine in combina-
tion with capecitabine [29]. A somewhat superior clinical
beneﬁt response rate was seen with the drug combination.
However, no advantage over single-agent gemcitabine was
noted in terms of objective eﬃcacy parameters.
The combination of gemcitabine and mitomycin C was
studied by Tuinmann et al. in a trial involving 55 patients
with advanced pancreatic cancer [30]. These patients were
given gemcitabine 800mg/m2 intravenously on days 1, 8,
and 15, and mitomycin C 8mg/m2 intravenously on day
1 every 4 weeks in an outpatient setting. A median of 3
cycles was administered. The most frequent toxicity was
thrombocytopenia grade III/IV seen in 54% of patients.
The objective response rate was 29%. Eighteen patients had
stable disease resulting in an overall tumor growth control
of 62%. Time to progression was 4.7 months, and median
overallsurvivalwas7.25months.Theauthorsconcludedthat
the combination was well tolerated. Survival was similar to
monotherapy with gemcitabine.6 International Journal of Surgical Oncology
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